NYSE:BAX • US0718131099
The current stock price of BAX is 20.985 USD. In the past month the price increased by 7.16%. In the past year, price decreased by -38.39%.
ChartMill assigns a technical rating of 4 / 10 to BAX. When comparing the yearly performance of all stocks, BAX is a bad performer in the overall market: 79.7% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to BAX. BAX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months BAX reported a non-GAAP Earnings per Share(EPS) of 2.27. The EPS decreased by -16.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.62% | ||
| ROE | -4.71% | ||
| Debt/Equity | 1.21 |
25 analysts have analysed BAX and the average price target is 23.61 USD. This implies a price increase of 12.49% is expected in the next year compared to the current price of 20.985.
For the next year, analysts expect an EPS growth of -0.01% and a revenue growth 2.3% for BAX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.91 | 200.474B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.45 | 174.759B | ||
| SYK | STRYKER CORP | 25.23 | 147.128B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.47 | 110.292B | ||
| BDX | BECTON DICKINSON AND CO | 11.61 | 52.52B | ||
| IDXX | IDEXX LABORATORIES INC | 43.79 | 49.757B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.81 | 47.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 38.219B | ||
| RMD | RESMED INC | 20.54 | 37.992B | ||
| DXCM | DEXCOM INC | 28.91 | 28.573B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
BAXTER INTERNATIONAL INC
One Baxter Parkway
Deerfield ILLINOIS 60015 US
CEO: Jose E. Almeida
Employees: 38000
Phone: 13026587581
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
The current stock price of BAX is 20.985 USD. The price decreased by -1.29% in the last trading session.
BAXTER INTERNATIONAL INC (BAX) has a dividend yield of 0.19%. The yearly dividend amount is currently 1.16.
BAX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BAX.
BAXTER INTERNATIONAL INC (BAX) has a market capitalization of 10.79B USD. This makes BAX a Large Cap stock.
The outstanding short interest for BAXTER INTERNATIONAL INC (BAX) is 6.95% of its float.